BRIDGEWATER, N.J. , Sept. 22, 2015 (GLOBE NEWSWIRE) — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported two ARIKAYCE™ (liposomal amikacin for inhalation) posters will be presented at the European Respiratory Society (ERS) International Congress taking place in Amsterdam from September 26-30.
Summarized below are the poster titles and presentation times.
Poster Title: Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
Lead Author: K. Olivier
Poster Number: PA371
Date: Sunday, September 27, 2015
Session Time: 08:30-10:30 AM
Session Title: Bronchiectasis and NTM infections: clinical aspects and research outlook
Poster Title: A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)
Lead Author: D. Griffith
Poster Number: PA3945
Date: Tuesday, September 29, 2015
Session Time: 12:50 PM-2:40 PM
Session Title: Novel strategies for the management of asthma, COPD and airway infections
Additional information about ERS 2015 can be found on the congress website at http://erscongress.org/. The posters will be made available on the Insmed’s website after presentation at the meeting.
Insmed Incorporated is a global biopharmaceutical company focused on the needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that can lead to progressive inflammation and lung damage. There are no currently approved treatments for NTM in the United States or European Union (EU). In the EU, the company has filed a marketing authorization application seeking approval of ARIKAYCE for use in patients with NTM, as well as in cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Insmed’s earlier-stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company is developing for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. To complement its internal research, Insmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information visit www.insmed.com.
CONTACT: Insmed Incorporated: Susan Mesco Head of Investor Relations 908-947-4326